Inflammatory bowel diseases (IBD) are a major health challenge due to their incidence and burdens, both financially and on patients’ wellbeing. Effective and well-tolerated therapeutic approaches are still direly needed for these multifactorial diseases. A promising diagnostic and therapeutic target are proteases. These enzymes are host- and microbiome-borne, and show an increased activity in the guts of IBD patients. Moreover the abundance of protease inhibitors is reduced in patients while we found that microbial antiproteases exert a protective effect against microbial protease-induced inflammation in rodents. To begin translating these discoveries in a human application, we measured the activity of protease families in 100 patients stratifying them into 4 groups, thereby allowing for a personalised approach to inhibiting deleterious protease activities. RestorPro will establish the proof of concept for a novel therapeutic pathway to restore protease homeostasis thanks to our unique library of new microbiota antiproteases. First, we will stratify 650 IBD patients by their protease activities, validate these novel biomarkers and design antiprotease combinations targeting patients' groups. Second, we will test the efficacy of these combinations in a human microbial co-culture gut-on-chip system integrating organoids from patients or healthy donors. Third, we will resolve the antiproteases modes-of-action using ex-vivo and in-vivo systems. RestorPro will fill important knowledge gaps on specific functions, modes-of-action, and inter-individual variability of human-microbiome interactions via protease/anti-protease activities in IBD condition and will provide proofs needed for further translation. For this goal, French and Luxembourgish experts joint their skills in protease-antiprotease activity in IBD, biomarker identification, gut-on-a-chip, organoids and murine models to better understand the interactions between the host and its microbiome in health and disease

In contexts of crimes, disasters, terrorism or population displacement that presently occurs in Europe and numerous regions of the world, the necessity of having as soon as possible reliable, high throughput and real time analysis to identify individuals, victims and authors is a major societal and legal issue. The present MRSEI ForOnBoardLab project aspire to strengthen a multidisciplinary consortium which was federated, during a PhD thesis, around the theme of the rapid DNA analysis in the aim to structure a project for answering to the European H2020 call "SU-FCT02-2018-2019-2020: Technologies to enhance the fight against crime and terrorism, Sub-topic 1: [2019]; Trace qualification" at the beginning of 2019. The ambition of our European project is to set up a technological and normative European st of references, procedures and guidelines in the field of the genetic identification using high throughput DNA fingerprints, in real time and on site. In this way the project also aims at developing innovative biological collection devices and smart and on-board mobile laboratory in agreement with standards and reglementations and qualify and validated instruments and analytical methods. This in situ and real time forensic approach involves 9 academic, institutional and industrial partners from 6 European countries: France, Switzerland, Greece, Italy, Luxembourg, Belgium with intrernationaly recognized forensic leaders in DNA analysis performing more than 150 000 expertises by year. ForOnBoardLab aims to initiate and catalyse during 18 months the consortium to propose a structuring program in the H2020. Such a support of the French ANR within the framework of the AAP MRSEI will enhance the emergence of an European network in the field of biological sampling integrated into solutions of analysis high throughput , in situ and real time DNA including trainings and normative functions in a guides of recommanded practices to collect traces in complex crimes/disasters or major population migrations fields

PARC is an EU-wide research and innovation partnership programme to support EU and national chemical risk assessment and risk management bodies with new data, knowledge, methods, networks and skills to address current, emerging and novel chemical safety challenges. PARC will facilitate the transition to next generation risk assessment to better protect human health and the environment, in line with the Green Deal?s zero-pollution ambition for a toxic free environment and will be an enabler for the future EU ?Chemicals Strategy for Sustainability?. It builds in part on the work undertaken and experience acquired in past and on-going research and innovation actions, but goes beyond by its vocation to establish an EU-wide risk assessment hub of excellence. To contribute to several expected impacts of destination 2 ?Living and working in a health-promoting environment?, PARC will organise the activities to reach three specific objectives: - An EU-wide sustainable cross-disciplinary network to identify and agree on research and innovation needs and to support research uptake into regulatory chemical risk assessment. - Joint EU research and innovation activities responding to identified priorities in support of current regulatory risk assessment processes for chemical substances and to emerging challenges. - Strengthening existing capacities and building new transdisciplinary platforms to support chemical risk assessment. The Partnership brings together Ministries and national public health and risk assessment agencies, as well as research organisations and academia from almost all of EU Member States. Representatives of Directorates-General of the EC and EU agencies involved in the monitoring of chemicals and the assessment of risks are also participating. PARC will meet the needs of risk assessment agencies to better anticipate emerging risks and respond to the challenges and priorities of the new European policies.

The COVID-19 pandemic has confirmed and further highlighted the importance of planning and investing in research and innovation well before a health crisis occurs. For this purpose, the main goal of BE READY is to build a consolidated European Research and Innovation Area that provides the foundation of the candidate European partnership for pandemic preparedness so to improve the EU's preparedness to predict and respond to emerging health threats by better coordinating funding for research and innovation at EU, national (and regional) level towards common objectives and an agreed Strategic Research and Innovation Agenda. The Partnership is expected to build on existing pandemic preparedness networks, and work in synergy with the Health Emergency Response Authority (HERA), in close collaboration with ECDC, EMA and other relevant international and European actors. BE READY is composed by 24 organisations from 15 countries with complementary expertise and policy area ranging from Public Health Organisations, Ministries (of Science, University, Health, Innovation or Environment) and Research Performing Organisations that ensures a cross-cutting, interdisciplinary Global Health and One Health approach.

BE READY PLUS aims to extend and enhance the efforts initiated by BE READY in preparing for pandemic response across Europe. The primary objective is to establish a robust and coordinated European Partnership (EP) for pandemic preparedness, fostering strategic alignment among Member States, Associated Countries, and key stakeholders. This will be achieved through the following key pillars: 1) Paving the way for the future European Partnership: BE READY PLUS will provide the necessary administrative and organizational support to ensure a smooth transition to the EP. This includes drafting operational procedures, governance frameworks, preparing requirements to launch Joint Transnational Calls, and engaging key stakeholders to create a solid research and innovation framework. 2) Paving the way for pandemic preparedness: The Strategic Research and Innovation Agenda (SRIA) established by BE READY will be disseminated and updated to reflect new research needs and gaps. BE READY PLUS will also prepare the ground for ever-warm networks of clinical, study sites across Europe, ensuring rapid response capabilities for future health threats. 3) Maximizing the impact of BE READY PLUS: This pillar ensures comprehensive communication and dissemination activities, leveraging digital platforms while maintaining crucial engagements. It aims to engage a wide range of stakeholders, from scientific communities to policymakers and the public, to foster collaboration and increase awareness about pandemic preparedness. BE READY PLUS builds on the successful foundation of BE READY, expanding the consortium to 31 partners from 21 countries, by the addition of 10 new partners and 5 new countries. We will work in synergy with a broad range of European stakeholders and initiatives. Overall, BE READY PLUS will contribute to a more resilient Europe by preparing a detailed operational framework, fostering strategic coordination, and ensuring readiness for swift response to future health crises.